• Users Online: 138
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 
Year : 2019  |  Volume : 3  |  Issue : 1  |  Page : 41-46

Biologicals in the management of rheumatodermatologic conditions and beyond

Department of Clinical Immunology and Rheumatology, Amrita Institute of Medical Sciences, Kochi, Kerala, India

Correspondence Address:
C B Mithun
Amrita Institute of Medical Sciences, Kochi, Kerala
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/CDR.CDR_51_18

Rights and Permissions

Biologicals are synthesized from living cells by biotechnology methods and typically include monoclonal antibodies and fusion proteins targeted against pathogenic cytokines, B or T cells, or its receptors. A biosimilar is a cheaper, manufactured product which is almost the same as biological. Appropriate patient selection is the key consideration before starting biologicals. Screening for tuberculosis is a must, except in case of rituximab. Tumor-necrosis-factor alpha inhibitors, interleukin (IL)-17A antagonists, anti-CD6 monoclonal antibodies (mAbs), and anti-IL-6 mAbs are discussed here for various indications.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded287    
    Comments [Add]    

Recommend this journal